NINTEDANIB
nintedanib 150 mg capsule, 60
NINTEDANIB (12953R)
12953R
Manner of administration:Oral
Restriction
Indication: Progressive fibrosing Interstitial lung disease
Treatment phase: Initial treatment
Restriction
Indication: Progressive fibrosing Interstitial lung disease
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 60 | # of repeats: 5 | DPMQ: $3,238.65 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Ofev | |||||